Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Pharmaceutical Care Network Europe (PCNE) proposed a definition and classification system (type 1, 2a, 2b, 3) for medication review in 2016. However, to date, a description of the implementation and remuneration of such procedures across Europe is lacking.
Objective: The aim of this study was to describe the medication review procedures and the level of implementation and remuneration in community pharmacies across Europe.
Methods: An online survey was developed to characterize medication review procedures (PCNE classification), level of implementation (considering regional or national) and remuneration by a third party. This survey was sent to a purposive sample of three individuals per country, with a working background in community pharmacy, pharmacy practice research, or health policy to ensure reliable data. Data triangulation was used and consensus sought between the responses.
Results: Data were received from 34 out of 44 targeted European countries (November 2016-October 2017) [response rate = 77%]. Overall, 55.9% of the countries provided at least one type of medication review as an implemented service or project. Type 1 medication review (based on the medication history) was provided in 13 countries, type 2a (medication history + patient interview) in 14, type 2b (medication history + clinical data) in two, and type 3 medication review (medication history + patient interview + clinical data) in four countries. Ten of the mentioned services or projects were remunerated by a third-party.
Conclusion: Substantial heterogeneity was observed across Europe in various aspects, including the procedures, implementation level and remuneration obtained. Type 1 and 2a medication review services seem to be more feasible to implement in the community pharmacy than type 2b and 3. A large number of medication review projects were ongoing in community pharmacies, which suggests that new medication review services could become implemented in the coming years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.sapharm.2019.11.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A systematic review of EEG-based machine learning classifications for obsessive-compulsive disorder: current status and future directions.
BMC Psychiatry
September 2025
Department of Cognitive Neuroscience, Faculty of Biology, Bielefeld University, Bielefeld, Germany.
Obsessive-compulsive disorder (OCD) is a chronic and disabling condition affecting approximately 3.5% of the global population, with diagnosis on average delayed by 7.1 years or often confounded with other psychiatric disorders.
View Article and Find Full Text PDF[Sodium-Glucose Cotransporter-2 (SGLT-2) inhibitors in perioperative medicine : Effects, side effects and current recommendations].
Anaesthesiologie
September 2025
Klinik für Anästhesiologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
Sodium-glucose Cotransporter 2 (SGLT-2) inhibitors are oral antidiabetic drugs that were developed for the treatment of patients with diabetes mellitus and are now also approved for treating chronic heart failure and chronic kidney disease. By inhibiting SGLT‑2 in the proximal renal tubule, urinary excretion of glucose is increased. Large randomized trials have demonstrated improved glycemic control, reduced cardiovascular events and lower mortality but also an increased risk of urogenital infections and dehydration.
View Article and Find Full Text PDFPatients with seizure disorders frequently present for anesthetic care, and anesthesiologists must be adequately equipped to manage these patients safely throughout the perioperative period. While Part I of this review focused on seizure diagnosis, classification, and treatment, Part II focuses on perioperative considerations for patients with seizure disorders. A detailed preoperative assessment is imperative as well as an in-depth understanding of the patient's medications and treatment modalities.
View Article and Find Full Text PDFMedication multiple experiences of elderly patient with multiple chronic condition: A qualitative meta-synthesis.
PLoS One
September 2025
Neonatology, Yan'an Hospital Affiliated to Kunming Medical University, Kunming City, Yunnan Province, China.
Purpose: To determine the experience of medication multiple in elderly patients with multiple chronic condition by systematically reviewing, retrieving, and synthesizing data from qualitative studies.
Methods: Nine databases were systematically searched for relevant contributions from the time of construction until October 30, 2024. All qualitative studies in English and Chinese exploring the real-life experiences, feelings, etc, of medication multiple in elderly patients with multiple chronic condition were included.
Promoting patients' empowerment in rheumatic diseases: the perspective of the International Society of Behçet's Disease Working Group on Patient Empowerment, Adherence to Therapy and Patients' Education.
Clin Exp Rheumatol
September 2025
Rheumatology Unit, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Behçet's disease (BD) is a rare multisystemic vasculitis that significantly impacts patients' quality of life. Effective management of BD requires a patient-centred approach that empowers individuals to actively participate in their care. This work explores the importance of patient empowerment, adherence to treatment, and patient education in BD.
View Article and Find Full Text PDF